N/A N=90 Randomized Double-blind Other

Examining the Feasibility and Acceptability of a Tailored Version of a Mindfulness-Based Intervention (MBI) Among Youth Experiencing Homelessness (YEH)

Stress, Emotional

Bottom Line

View on ClinicalTrials.gov: NCT04950816 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Aug 2025

Primary outcome: Primary: Emotion Regulation as Measured by Difficulties in Emotion Regulation Scale (DERS) — 93.18; 82.62 score on a scale

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: tailored MBI (.b) (Behavioral); attention control condition (Behavioral)
Age: Adult · 18+ yrs
Sex: All
Sponsor: The University of Texas Health Science Center, Houston
Primary completion: Jun 2024

Outcome Measures

Outcome	Result	p-value
PRIMARY Emotion Regulation as Measured by Difficulties in Emotion Regulation Scale (DERS)	90.36; 94.26	—
PRIMARY Emotion Regulation as Measured by Difficulties in Emotion Regulation Scale (DERS)	90.36; 94.26	—
PRIMARY Emotion Regulation as Measured by Difficulties in Emotion Regulation Scale (DERS)	90.36; 94.26	—
PRIMARY Emotion Regulation as Measured by Difficulties in Emotion Regulation Scale (DERS)	90.36; 94.26	—
PRIMARY Mindfulness as Measured by Child and Adolescent Mindfulness Measure (CAMM)	25.92; 30.36	—
PRIMARY Mindfulness as Measured by Child and Adolescent Mindfulness Measure (CAMM)	25.92; 30.36	—
PRIMARY Mindfulness as Measured by Child and Adolescent Mindfulness Measure (CAMM)	25.92; 30.36	—
PRIMARY Mindfulness as Measured by Child and Adolescent Mindfulness Measure (CAMM)	25.92; 30.36	—
PRIMARY Mindfulness as Measured by Cognitive and Affective Mindfulness Scale-Revised (CAMS-R)	—	—
PRIMARY Self-Compassion as Measured by Self-Compassion Scale (SCS)	3.23; 3.06	—
PRIMARY Self-Compassion as Measured by Self-Compassion Scale (SCS)	3.23; 3.06	—
PRIMARY Self-Compassion as Measured by Self-Compassion Scale (SCS)	3.23; 3.06	—
PRIMARY Self-Compassion as Measured by Self-Compassion Scale (SCS)	3.23; 3.06	—
PRIMARY Stress as Measured by Perceived Stress Scale (PSS)	18.48; 18.65	—
PRIMARY Stress as Measured by Perceived Stress Scale (PSS)	18.48; 18.65	—
PRIMARY Stress as Measured by Perceived Stress Scale (PSS)	18.48; 18.65	—
PRIMARY Stress as Measured by Perceived Stress Scale (PSS)	18.48; 18.65	—
PRIMARY Feasibility as Assessed by the Percentage of Participants Enrolled in the Study	90	—
PRIMARY Feasibility as Assessed by the Number of Participants Who Adhere to Treatment	35; 41	—
PRIMARY Feasibility as Assessed by the Number of Participants Who Completed the 3 Months Follow up	31; 28	—
PRIMARY Feasibility as Assessed by the Number of Participants Who Completed the 6 Months Follow up	25; 24	—
PRIMARY Acceptability as Assessed by the Credibility and Expectancy Questionnaire - Expectancy Subscale	7.05; 6.09	—
PRIMARY Acceptability as Assessed by the Credibility and Expectancy Questionnaire - Credibility Subscale	7.56; 6.53	—
SECONDARY Social Connectedness as Measured Social Connectedness Scale	26.32; 32.26	—
SECONDARY Social Connectedness as Measured Social Connectedness Scale	26.32; 32.26	—
SECONDARY Social Connectedness as Measured Social Connectedness Scale	26.32; 32.26	—
SECONDARY Social Connectedness as Measured Social Connectedness Scale	26.32; 32.26	—
SECONDARY Depression as Measured by Short Mood and Feelings Questionnaire (SMFQ)	—	—
SECONDARY Anxiety as Measured by Spielberger State-Trait Anxiety Inventory	—	—
SECONDARY Vulnerability as Measured by Psychological Vulnerability Scale	14.2; 12.27	—
SECONDARY Vulnerability as Measured by Psychological Vulnerability Scale	14.2; 12.27	—
SECONDARY Vulnerability as Measured by Psychological Vulnerability Scale	14.2; 12.27	—
SECONDARY Vulnerability as Measured by Psychological Vulnerability Scale	14.2; 12.27	—
SECONDARY Risk Seeking as Measured by Balloon Analogue Risk Task (BART)	—	—
SECONDARY Distress as Measured by Kessler Psychological Distress Scale (K10)	—	—
SECONDARY Number of Participants Who Are Sexually Active	20; 16	—
SECONDARY Number of Participants Who Are Sexually Active	20; 16	—
SECONDARY Number of Participants Who Are Sexually Active	20; 16	—
SECONDARY Number of Participants Who Are Sexually Active	20; 16	—
SECONDARY Number of Participants Who Ever Used Drugs or Substances (Marijuana, Prescription Pain Medicine Without a Prescription, Synethic Marijuana, Cocaine, Inhalants, Heroin, Meth, Ecstasy, Injection Drugs)	19; 17	—
SECONDARY Number of Participants Who Ever Used Drugs or Substances (Marijuana, Prescription Pain Medicine Without a Prescription, Synethic Marijuana, Cocaine, Inhalants, Heroin, Meth, Ecstasy, Injection Drugs)	19; 17	—
SECONDARY Number of Participants Who Ever Used Drugs or Substances (Marijuana, Prescription Pain Medicine Without a Prescription, Synethic Marijuana, Cocaine, Inhalants, Heroin, Meth, Ecstasy, Injection Drugs)	19; 17	—
SECONDARY Number of Participants Who Ever Used Drugs or Substances (Marijuana, Prescription Pain Medicine Without a Prescription, Synethic Marijuana, Cocaine, Inhalants, Heroin, Meth, Ecstasy, Injection Drugs)	19; 17	—
SECONDARY Depression as Measured by Patient Health Questionnaire-9 (PHQ-9)	9.52; 7.04	—
SECONDARY Depression as Measured by Patient Health Questionnaire-9 (PHQ-9)	9.52; 7.04	—
SECONDARY Depression as Measured by Patient Health Questionnaire-9 (PHQ-9)	9.52; 7.04	—
SECONDARY Depression as Measured by Patient Health Questionnaire-9 (PHQ-9)	9.52; 7.04	—
SECONDARY Anxiety as Measured by Generalized Anxiety Disorder (GAD) Scale	8.04; 5.04	—
SECONDARY Anxiety as Measured by Generalized Anxiety Disorder (GAD) Scale	8.04; 5.04	—
SECONDARY Anxiety as Measured by Generalized Anxiety Disorder (GAD) Scale	8.04; 5.04	—
SECONDARY Anxiety as Measured by Generalized Anxiety Disorder (GAD) Scale	8.04; 5.04	—
SECONDARY Distress as Measured by PROMIS Item Bank v.1.0-Emotional Distress	17.76; 14.39	—
SECONDARY Distress as Measured by PROMIS Item Bank v.1.0-Emotional Distress	17.76; 14.39	—
SECONDARY Distress as Measured by PROMIS Item Bank v.1.0-Emotional Distress	17.76; 14.39	—
SECONDARY Distress as Measured by PROMIS Item Bank v.1.0-Emotional Distress	17.76; 14.39	—
SECONDARY Risk Seeking as Measured by Risk Propensity Scale.	40.97; 46.35	—
SECONDARY Risk Seeking as Measured by Risk Propensity Scale.	40.97; 46.35	—
SECONDARY Risk Seeking as Measured by Risk Propensity Scale.	40.97; 46.35	—
SECONDARY Risk Seeking as Measured by Risk Propensity Scale.	40.97; 46.35	—
SECONDARY Executive Function as Measured by the Amsterdam Executive Function Inventory (AEFI)	2.04; 2.05	—
SECONDARY Executive Function as Measured by the Amsterdam Executive Function Inventory (AEFI)	2.04; 2.05	—
SECONDARY Executive Function as Measured by the Amsterdam Executive Function Inventory (AEFI)	2.04; 2.05	—
SECONDARY Executive Function as Measured by the Amsterdam Executive Function Inventory (AEFI)	2.04; 2.05	—
SECONDARY Positive Affect as Measured by Positive and Negative Affect Scale (PANAS-SF)	34.22; 31.49	—
SECONDARY Positive Affect as Measured by Positive and Negative Affect Scale (PANAS-SF)	34.22; 31.49	—
SECONDARY Negative Affect as Measured by Positive and Negative Affect Scale (PANAS-SF)	17.88; 18.54	—
SECONDARY Negative Affect as Measured by Positive and Negative Affect Scale (PANAS-SF)	17.88; 18.54	—

Summary

The purpose of this study is to conduct a trial of the tailored Mindfulness- Based Intervention (MBI) (.b) vs. attention control to test real-world feasibility and acceptability of this tailored Mindfulness - Based Intervention (MBI) in youth experiencing homelessness (YEH).

Eligibility Criteria

Inclusion Criteria

homeless youth receiving services at one of the recruitment sites in Houston, Texas area at the time of enrollment
English speaking
able to participate for the entire study period (i.e., not moving during the study)

Exclusion Criteria

overtly exhibiting symptoms of severe, untreated mental illness criteria
not staying at the shelter
currently experiencing homelessness or unstable housing

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04950816). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.